Tissue Engineering Microtia Auricular Reconstruction: in Vitro and in Vivo Studies


Platelet-rich plasma (PRP) has mixed growth factors such as TGF-ß1 and TGF-ß2, vascular epithelial growth factor (VEGF), platelet-derived growth factor (PDGF), and insulin-like growth factor (IGF). These growth factors appear to play an important role in wound healing and are assumed as promoters of tissue regeneration. Moreover, PRP was used as injectable scaffold seeded with chondrocytes to regenerate cartilage. In their previous study, the investigators concluded that growth factors in PRP can effectively react as a growth factor cocktail to induce human nucleus pulposus proliferation and differentiation, and also promote tissue-engineered nucleus pulposus formation. The investigators also have a hypothesis that PRP can promote tissue-engineered microtia auricular cartilage formation. TGF- ß1 exists in the highest concentration and is more important among all of the growth factors released from PRP. So TGF- ß1 can be used as the core ingredient and the indicator for applying PRP in these studies. The aim of this study was to compare the histological and biochemical character of microtia chondrocytes treated with and without PRP.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: August 2009


  • Other: Platelet-rich plasma (PRP)
    • PRP was extracted from total blood and TGF-b1 was used as indicator
  • Other: Chondrocyte culture with FBS medium
    • Microtia chondrocyte culture with FBS medium only

Arms, Groups and Cohorts

  • Placebo Comparator: Arm A
    • Chondrocyte culture with FBS medium
  • Experimental: Arm B
    • Chondrocyte culture with PRP

Clinical Trial Outcome Measures

Primary Measures

  • The aim of this study was to compare the histological and biochemical character of microtia chondrocytes treated with and without PRP.
    • Time Frame: 4 weeks

Participating in This Clinical Trial

Inclusion Criteria

  • microtia patient Exclusion Criteria:

  • non microtia patient

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Taipei Medical University WanFang Hospital
  • Provider of Information About this Clinical Study
    • Chia-Che Wu, MD, Taipei medical university- Wan Fang Hospital
  • Overall Official(s)
    • Chia-Che Wu, MD, Study Chair, Chia-Che Wu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.